🚀 VC round data is live in beta, check it out!
Pliant Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pliant Therapeutics and similar public comparables like Seres Therapeutics, PolyPid, Lytix Biopharma, OKYO Pharma and more.
Pliant Therapeutics Overview
About Pliant Therapeutics
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Founded
2015
HQ
Employees
171
Website
Sectors
Financials (LTM)
Market Cap
$84M
Pliant Therapeutics Financials
Pliant Therapeutics reported last 12-month revenue of — and negative EBITDA of ($139M).
In the same LTM period, Pliant Therapeutics generated — in gross profit, ($139M) in EBITDA losses, and had net loss of ($134M).
Revenue (LTM)
Pliant Therapeutics P&L
In the most recent fiscal year, Pliant Therapeutics reported revenue of — and EBITDA of ($145M).
Pliant Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($139M) | XXX | ($145M) | XXX | XXX | XXX |
| Net Profit | ($134M) | XXX | ($149M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pliant Therapeutics Stock Performance
Pliant Therapeutics has current market cap of $84M.
Market Cap Evolution
Pliant Therapeutics' stock price is $1.35.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $84M | -0.7% | XXX | XXX | XXX | $-2.41 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPliant Therapeutics Valuation Multiples
Pliant Therapeutics trades at 0.6x EV/EBITDA.
EV / Revenue (LTM)
Pliant Therapeutics Financial Valuation Multiples
As of April 10, 2026, Pliant Therapeutics has market cap of $84M.
Equity research analysts estimate Pliant Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pliant Therapeutics has a P/E ratio of (0.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $84M | XXX | $84M | XXX | XXX | XXX |
| EV (current) | ($78M) | XXX | ($78M) | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBIT | 0.6x | XXX | 0.5x | XXX | XXX | XXX |
| P/E | (0.6x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/FCF | 0.7x | XXX | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pliant Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pliant Therapeutics Margins & Growth Rates
Pliant Therapeutics' revenue in the last fiscal year declined by (100%).
Pliant Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Pliant Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | (33%) | XXX | (36%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pliant Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Seres Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| PolyPid | XXX | XXX | XXX | XXX | XXX | XXX |
| Lytix Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| OKYO Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Eco Animal Health Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pliant Therapeutics M&A Activity
Pliant Therapeutics acquired XXX companies to date.
Last acquisition by Pliant Therapeutics was on XXXXXXXX, XXXXX. Pliant Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pliant Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPliant Therapeutics Investment Activity
Pliant Therapeutics invested in XXX companies to date.
Pliant Therapeutics made its latest investment on XXXXXXXX, XXXXX. Pliant Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pliant Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pliant Therapeutics
| When was Pliant Therapeutics founded? | Pliant Therapeutics was founded in 2015. |
| Where is Pliant Therapeutics headquartered? | Pliant Therapeutics is headquartered in United States. |
| How many employees does Pliant Therapeutics have? | As of today, Pliant Therapeutics has over 171 employees. |
| Who is the CEO of Pliant Therapeutics? | Pliant Therapeutics' CEO is Bernard Coulie. |
| Is Pliant Therapeutics publicly listed? | Yes, Pliant Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Pliant Therapeutics? | Pliant Therapeutics trades under PLRX ticker. |
| When did Pliant Therapeutics go public? | Pliant Therapeutics went public in 2020. |
| Who are competitors of Pliant Therapeutics? | Pliant Therapeutics main competitors are Seres Therapeutics, PolyPid, Lytix Biopharma, OKYO Pharma. |
| What is the current market cap of Pliant Therapeutics? | Pliant Therapeutics' current market cap is $84M. |
| Is Pliant Therapeutics profitable? | No, Pliant Therapeutics is not profitable. |
| What is the current EBITDA of Pliant Therapeutics? | Pliant Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Pliant Therapeutics? | Current EBITDA multiple of Pliant Therapeutics is 0.6x. |
| What is the current FCF of Pliant Therapeutics? | Pliant Therapeutics' last 12 months FCF is ($115M). |
| What is the current EV/FCF multiple of Pliant Therapeutics? | Current FCF multiple of Pliant Therapeutics is 0.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.